# Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout

> **NCT00170781** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 234 (—)

## Conditions studied

- Acute Gouty Arthritis

## Interventions

- **DRUG:** Lumiracoxib

## Key facts

- **NCT ID:** NCT00170781
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 234 (—)
- **Last updated:** 2006-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00170781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00170781, "Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00170781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*